

Voluntary Disclosure of GSK in Canada payments to HCPs and HCOs in 2018



Our commitment to transparency



We understand that our role in providing HCPs with new data and information about our medicines must be done clearly and without any perception of conflict of interest. We believe that transparent scientific dialogue and engagement with experts is in the best interests of all those working to develop new medicines, improve clinical practice and care for patients.

We are pioneers



Since 2017, GSK has voluntarily agreed to publicly report aggregate payments made to HCPs and HCOs. We believe this was a great first step. We are proud to be leaders in expanding our reporting of payments to individual HCPs from 2019, despite the lack of disclosure requirements in Canada.

The important relationship between industry and HCPs

The relationship between healthcare companies and HCPs is an essential part of patient care, disease understanding as well as the research and discovery of innovative medicines in Canada. By continuing to be transparent of these relationships, we are evolving with society's expectations.



Collaborations

GSK collaborates with HCPs and HCOs to foster scientific exchange which benefit patients.

Collaborations are bound by local and international laws and regulated by Innovative Medicines Canada's [Code of Ethical Practices](#).



What are payments or transfers of value?

They are collaborations and contributions, both monetary and non-monetary made to HCPs and HCOs.



What are the collaborations for?

- Grants to HCOs.
- Training activities and scientific professional meetings.
- R&D activities.
- Provision of services such as consulting.



What does aggregate disclosure mean?

We are publishing data in aggregate, a consolidated total of all payments made to HCPs and HCOs per category.

Voluntary Disclosure of GSK in Canada payments to HCPs and HCOs in 2018

The Figures

GSK's voluntary decision to publish our payments to HCPs and HCOs is part of our commitment to greater transparency and high ethical standards in our business practices. The "**Voluntary Framework on Disclosure**" was developed by **Innovative Medicines Canada**.

All payment information is captured in aggregate form (one sum total) and presented below in **three categories**:

\$2,336,747
Fees for HCP Services

\$1,160,235
Funding to HCOs

\$0
Sponsorship of HCP Travel

Total Payments of all categories **\$3,496,982**



\$820,684,287

2018 GSK in Canada Sales

Payments represent **0.43%** of Sales



\$65,571,479

GSK invested into Canada R&D in 2018

R&D as a % of Sales: **7.99%**



\$674,000

Our 2018 Community Groups Grants and Donations total

GSK also provides and publishes funding made to patient groups. To view 2018 funding click [here](#).

For clarity purposes only, please note the following:

- Applicable taxes may be included or excluded.
- The values provided may include certain related incidental expenses (such as, but not limited to, mileage reimbursement for travel).
- Transfer of Value (ToV) is captured according to the General Ledger date and not necessarily the date on which payment was made. Therefore, some activities in 2017 are reported as ToVs in 2018, and some activities that occurred in 2018 will be reported in the 2019 report.
- Payments made to HCOs may include payments that were passed through to HCPs as fee for service and, if so, will be captured in either category 1 or category 2, but the same payment will not be captured in both categories.
- Total funding to HCOs may also include payments to Patient Associations, as the reporting system does not have the functionality to separate out such payments.
- GSK has used its reasonable best efforts to capture the most comprehensive data possible according to its knowledge and interpretation of the Voluntary Framework of Payments to HCPs/HCOs.

NOTE: While GSK makes every effort to present accurate and reliable information, the Company makes no warranty and assumes no legal liability or responsibility for the accuracy or completeness of the information contained herein. The Company shall not be liable for damages resulting from the use or misuse of the information contained on this website. Certain links may lead to resources located on servers that are not maintained by Company or under its control, and such hypertext links are provided as a convenience only. The inclusion of a link does not imply endorsement by or of the referenced site and the Company is not responsible for the contents of or the availability of access to such websites.